首页> 外文期刊>European journal of cancer prevention: The official journal of the European Cancer Prevention Organisation (ECP) >Risk of second primary cancers, other than melanoma, in an Italian population-based cohort of cutaneous malignant melanoma patients.
【24h】

Risk of second primary cancers, other than melanoma, in an Italian population-based cohort of cutaneous malignant melanoma patients.

机译:在意大利人群为基础的皮肤恶性黑色素瘤患者队列中,除了黑色素瘤以外,还有其他继发原发癌的风险。

获取原文
获取原文并翻译 | 示例
       

摘要

A population-based study has been carried out in central Italy to investigate the risk of further non-melanoma primary cancers in a cohort of cutaneous malignant melanoma (CMM) patients. We considered 1835 invasive CMM cases (93.4% histologically verified) diagnosed between 1985 and 1999 by the Tuscany Cancer Registry, central Italy (1 200000 inhabitants) and actively followed up to the end of 1999 for vital status and for the occurrence of a second primary. Only cases diagnosed after 2 months (metachronous) from CMM diagnosis were considered. During 7758 person-years of observation, 94 cancers were observed (93.6% histologically verified) versus 73.8 expected, corresponding to a standardized incidence ratio (SIR) of 1.27 (95% confidence interval (CI) 1.03-1.56). The risk was similarly increased in both sexes, males SIR=1.31 and females SIR=1.23, and it was statistically significant among subjects younger than 60 years (SIR=1.76) but not among those of 60 years and older (SIR=1.14). Significant increased risks were observed for non-melanoma skin cancers (SIR=3.26) and non-Hodgkin's lymphoma (SIR=2.74). Physicians should be aware of the higher risk for non-Hodgkin's lymphoma and clinical follow-up should include lymph node palpation. However, the risk for extranodal lymphomas should also be kept in mind.
机译:在意大利中部已经进行了一项基于人群的研究,以调查皮肤恶性黑色素瘤(CMM)患者队列中进一步发生非黑色素瘤原发癌的风险。我们考虑了意大利中部托斯卡纳癌症登记处在1985年至1999年之间诊断的1835例侵入性CMM病例(93.4%经过组织学证实)(1 2000 000居民),并积极随访至1999年底,以维持生命状态和第二例原发性。仅考虑从CMM诊断开始2个月后(同步)诊断的病例。在7758人年的观察期间,观察到94种癌症(经组织学证实为93.6%)对预期的73.8种癌症,对应于1.27(95%置信区间(CI)1.03-1.56)的标准化发生率(SIR)。男性SIR = 1.31和女性SIR = 1.23的男女患病风险相似地增加,在60岁以下的受试者(SIR = 1.76)中有统计学意义,而60岁以上的受试者(SIR = 1.14)却没有统计学意义。观察到非黑色素瘤皮肤癌(SIR = 3.26)和非霍奇金淋巴瘤(SIR = 2.74)的风险显着增加。医师应意识到非霍奇金淋巴瘤的较高风险,临床随访应包括淋巴结触诊。但是,也应注意结外淋巴瘤的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号